Bactiguard Holding AB (BACTI.B) AI Stock Analysis

• Market Cap: kr1.05B
• Dividend Yield: N/A
• Average Volume (3M): 6.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: 23.51%
• EPS Growth: 80.47%
• Country: SE
• Employees: 147
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.70
• Shares Outstanding: 31,043,884
• 10 Day Avg. Volume: 4,616
• 30 Day Avg. Volume: 6,347
• PEG Ratio: -2.37
• Price to Book (P/B): 3.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 43.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr29.99
• Price Target Upside: -15.52% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: kr31.00 ▼(-12.68%Downside)

The overall stock score of 46 reflects significant financial challenges, most notably negative profitability margins and increasing leverage. Technical indicators suggest mild bearish momentum, while the valuation score is severely impacted by the negative P/E ratio and lack of dividend yield. The company must focus on improving financial performance to enhance its market position.

Bactiguard Holding AB Business Overview & Revenue Model

Company Description

Bactiguard Holding AB is a Swedish medical technology company that specializes in infection prevention solutions. The company operates primarily within the healthcare sector, providing innovative products designed to reduce the risk of healthcare-associated infections. Bactiguard's core offerings include its proprietary coating technology, which is applied to medical devices such as catheters and implants to minimize bacterial adhesion and biofilm formation, effectively lowering the incidence of infections.

How the Company Makes Money

Bactiguard Holding AB generates revenue through the production and licensing of its infection prevention technologies. The company's primary revenue streams include direct sales of coated medical devices and licensing agreements with other medical device manufacturers who integrate Bactiguard's coating technology into their products. Significant partnerships with global medical technology companies also play a crucial role in driving sales and expanding market reach. The company benefits from a growing demand for infection control solutions in healthcare settings, which is a key factor contributing to its earnings.

Bactiguard Holding AB Financial Statement Overview

Summary

Bactiguard Holding AB is navigating through financial challenges characterized by inconsistent revenue growth, negative profitability margins, and increasing leverage. The improvements in operational cash flow are encouraging but need to be sustained to strengthen financial health. Efforts to enhance revenue growth and profitability will be crucial to improving the overall financial standing of the company.

Income Statement

Bactiguard Holding AB shows a mixed performance in its income statement. The company has experienced a decline in its gross profit and net income over the years, indicating challenges in maintaining profitability. The TTM data reveals a negative EBIT and net profit margin, highlighting operational inefficiencies. Revenue growth is inconsistent, with recent declines suggesting potential demand issues in the market.

Balance Sheet

The balance sheet reflects a moderately stable financial position. The debt-to-equity ratio is reasonable but has shown a slight increase over time, indicating rising leverage. Return on equity is negative, impacted by consistent net losses. The equity ratio provides some stability, but the declining trend in stockholders' equity poses a risk of financial distress if not addressed.

Cash Flow

Cash flow from operations has improved in the TTM period, turning positive after a previous negative trend. However, free cash flow remains relatively low, limiting financial flexibility. The operating cash flow to net income ratio is positive, suggesting improved cash conversion from earnings, but the overall cash flow position requires careful monitoring to ensure sustainable liquidity.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
258.60M	243.68M	203.99M	223.56M	169.49M	172.31M
	Gross Profit
164.57M	207.71M	139.98M	180.14M	130.80M	137.12M
	EBIT
-20.80M	-28.86M	-131.93M	-54.23M	-51.19M	-21.85M
	EBITDA
38.06M	24.99M	-89.98M	-543.00K	-5.94M	9.21M
	Net Income Common Stockholders
-24.64M	-29.82M	-138.38M	-52.88M	-58.77M	-38.39M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
46.81M	116.73M	123.22M	197.73M	217.59M	9.89M
	Total Assets
575.58M	655.91M	662.17M	807.70M	849.29M	675.22M
	Total Debt
171.23M	227.77M	233.10M	238.70M	247.96M	264.02M
	Net Debt
124.42M	111.04M	109.88M	40.97M	30.37M	254.14M
	Total Liabilities
257.89M	327.57M	309.00M	311.99M	307.84M	301.87M
	Stockholders Equity
317.68M	328.34M	353.18M	495.71M	541.45M	373.35M
Cash Flow		Free Cash Flow
23.25M	10.21M	-60.94M	-7.86M	-38.00K	-14.65M
	Operating Cash Flow
31.93M	24.99M	-52.33M	3.06M	7.26M	702.00K
	Investing Cash Flow
-8.68M	-14.78M	-8.61M	-10.92M	-7.29M	-57.01M
	Financing Cash Flow
-70.36M	-21.20M	-11.84M	-13.89M	205.83M	46.20M

Bactiguard Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 35.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Negative. The current price of 35.5 is above the 20-day moving average (MA) of 34.22, above the 50-day MA of 31.83, and below the 200-day MA of 39.25, indicating a bearish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 37.16 is Neutral, neither overbought nor oversold. The STOCH value of 21.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BACTI.B.

Bactiguard Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.15B	35.49	10.11%	―	2.53%	-44.90%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
INTEG.B	53 Neutral	€430.95M	―	-19.17%	―	-12.50%	-783.92%
SEDANA	52 Neutral	kr1.21B	―	-5.61%	―	13.66%	-139.90%
BRAIN	50 Neutral	kr395.29M	―	-33.54%	―	72.05%	33.68%
MNTC	49 Neutral	kr531.83M	―	-17.16%	―	17.75%	18.05%
BACTI.B	46 Neutral	kr1.05B	―	-7.30%	―	23.51%	80.47%

Bactiguard Holding AB Corporate Events

Bactiguard AGM Decisions: No Dividend and Board Re-elections

At Bactiguard Holding AB’s Annual General Meeting, it was decided that no dividend will be paid for the financial year 2024, with retained earnings carried forward. The Board of Directors and CEOs were discharged from liability, and remuneration was set for the board members. Key board members, including Thomas von Koch as Chairman, were re-elected, and Deloitte AB was re-elected as auditor. The AGM also authorized the Board to issue new shares, warrants, and convertibles, which could impact the company’s financial strategy and shareholder value.

The most recent analyst rating on ($SE:BACTI.B) stock is a Hold with a SEK30.00 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.